Morphosys (MOR) PT Set at €85.00 by Berenberg Bank
Morphosys (ETR:MOR) has been given a €85.00 ($101.19) price objective by equities research analysts at Berenberg Bank in a report issued on Thursday. The firm currently has a “buy” rating on the stock. Berenberg Bank’s price objective suggests a potential upside of 8.42% from the company’s previous close.
Several other brokerages have also recently commented on MOR. Commerzbank set a €76.00 ($90.48) target price on shares of Morphosys and gave the stock a “buy” rating in a report on Tuesday, November 7th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a target price on shares of Morphosys in a report on Thursday, November 2nd. Goldman Sachs Group set a €55.00 ($65.48) target price on shares of Morphosys and gave the stock a “neutral” rating in a report on Tuesday, September 19th. Deutsche Bank set a €90.00 ($107.14) price target on shares of Morphosys and gave the stock a “buy” rating in a research report on Monday, October 30th. Finally, Independent Research set a €77.00 ($91.67) price target on shares of Morphosys and gave the stock a “buy” rating in a research report on Thursday, September 7th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of €82.25 ($97.92).
Morphosys (ETR:MOR) traded up €0.23 ($0.27) during mid-day trading on Thursday, reaching €78.40 ($93.33). 63,567 shares of the company traded hands, compared to its average volume of 199,542. Morphosys has a 1 year low of €40.10 ($47.74) and a 1 year high of €83.78 ($99.74).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for Morphosys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys AG and related companies with MarketBeat.com's FREE daily email newsletter.